Skip to content
Sample Page
Author:
Entera Bio Ltd.
Posted Date:
June 22, 2026
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 – the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
Entera Bio Ltd.
June 22, 2026